Европейски съюз - английски - EMA (European Medicines Agency)

teva pharma b.v. - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Европейски съюз - английски - EMA (European Medicines Agency)

amneal pharma europe ltd - levodopa, carbidopa - parkinson disease - anti-parkinson drugs - symptomatic treatment of adult patients with parkinson’s disease

Европейски съюз - английски - EMA (European Medicines Agency)

viatris healthcare limited - tolcapone - parkinson disease - anti-parkinson drugs, other dopaminergic agents - tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-o-methyltransferase (comt) inhibitors.because of the risk of potentially fatal, acute liver injury, tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.since tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with tasmar.

Европейски съюз - английски - EMA (European Medicines Agency)

teva pharma b.v. - pramipexole dihydrochloride monohydrate - parkinson disease - anti-parkinson drugs - pramipexole teva is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).pramipexole teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

Европейски съюз - английски - EMA (European Medicines Agency)

krka, d.d., novo mesto - pramipexole dihydrochloride monohydrate - parkinson disease - anti-parkinson drugs - oprymea is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

Европейски съюз - английски - EMA (European Medicines Agency)

accord healthcare s.l.u. - pramipexole dihydrochloride monohydrate - parkinson disease; restless legs syndrome - anti-parkinson drugs - pramipexole accord is indicated in adults for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).

Европейски съюз - английски - EMA (European Medicines Agency)

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Европейски съюз - английски - EMA (European Medicines Agency)

teva b.v. - rasagiline - parkinson disease - anti-parkinson drugs - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.

Европейски съюз - английски - EMA (European Medicines Agency)

teva b.v. - rasagiline - parkinson disease - anti-parkinson drugs - rasagiline ratiopharm is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Европейски съюз - английски - EMA (European Medicines Agency)

zambon spa - safinamide methanesulfonate - parkinson disease - anti-parkinson drugs - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.